Liver kinase B1 (LKB1) is a serine/threonine protein kinase ubiquitously expressed in mammalian cells. It was first identified in Peutz-Jeghers syndrome as a tumor suppressor gene. Whether endothelial LKB1 regulates angiogenesis and tumor growth is unknown. In this study, we generated endothelial cell-specific LKB1-knockout (LKB1 endo − / − ) mice by crossbreeding vascular endothelialcadherin-Cre mice with LKB1 flox/flox mice. Vascular endothelial growth factor (VEGF) level was highly co-stained in endothelial cells but not in macrophages in LKB1 endo − / − mice. Consistently, LKB1 endo − / − mouse tissues including the lung, skin, kidney and liver showed increased vascular permeability. Tumors implanted in LKB1 endo − / − mice but not macrophage-specific LKB1-knockout mice grew faster and showed enhanced vascular permeability and increased angiogenesis as compared with those implanted in wildtype mice. Injection of VEGF-neutralizing antibody but not the isotype-matched control antibody decreased endothelial-cell angiogenesis and tumor growth in vivo. Furthermore, LKB1 deletion enhanced mouse retinal and cell angiogenesis, and knockdown of VEGF by small-interfering RNA decreased endothelial cell proliferation and migration. Re-expression of LKB1 or knockdown of VEGF receptor 2 decreased the overproliferation and -migration observed in LKB1 endo − / − cells. Mechanistically, LKB1 could bind to the VEGF transcription factor, specificity protein 1 (Sp1), which then inhibited the binding of Sp1 to the VEGF promoter to reduce VEGF expression. Endothelial LKB1 may regulate endothelial angiogenesis and tumor growth by modulating Sp1-mediated VEGF expression.
INTRODUCTION
Angiogenesis is the physiological process, whereby new blood vessels are formed from pre-existing vessels. It is crucial for growth, development and postnatal organ repair. Angiogenesis also contributes to several pathological conditions, including cancer, by supplying nutrients and oxygen to maintain aggressive growth. 1 Vascular endothelial growth factor (VEGF) signaling has an essential role in physiological and pathological angiogenesis. 2 The VEGF family consists of VEGF-A, VEGF-B, VEGF-C, VEGF-D and placenta growth factor. VEGF-A, first described as a vascular permeability factor, 3 binds to its cell-surface receptors including VEGF receptor 1 (VEGFR1), VEGFR2 and neuropilin-1/2 on endothelial cells (ECs). This binding dimerizes and authophosphorylates the receptor and starts the signaling cascades required for EC proliferation and migration. 4 VEGF-A has a critical role in angiogenesis; VEGF-A-knockout mice are lethal embryonically because of abnormal vascular development. 5 Although VEGF-A (hereafter VEGF) is well known to regulate angiogenesis, how it is regulated remains poorly understood.
VEGF expression is regulated at many levels including transcription, translation and mRNA stability. 6, 7 Under various conditions, VEGF is upregulated by transcriptional factors such as specificity protein 1 (Sp1), signal transducer and activator of transcription 3 and hypoxia-inducible factor-1. 8 Sp1 has 785 amino acids and regulates VEGF expression by binding to GC-rich motifs within the promoter. 9 Sp1 downregulation reduces tumor vascularization; 8 therefore, it may have an antitumor role. Given the important roles of VEGF in angiogenesis, a complete understanding of its regulation is significant to elucidate the process of angiogenesis.
Liver kinase B1 (LKB1) is a serine/threonine protein kinase and is ubiquitously expressed in mammalian cells. It was first identified in Peutz-Jeghers syndrome as a tumor suppressor. 10, 11 LKB1 can phosphorylate the adenosine monophosphate-activated protein kinase (AMPK) family of proteins, including 14 members, and have an important role in energy metabolism and cell polarity. 12, 13 Many LKB1-knockout mouse models have been generated to further elucidate the in vivo roles. 14 We previously showed that LKB1 overexpression inhibits endothelial tube formation, 15 which suggests that LKB1 is anti-angiogenic. However, the detailed mechanism for this formation is unknown. In this study, we used endothelium-specific LKB1-knockout mice (LKB1 endo − / − ) 16 to show that LKB1 deletion in ECs promoted tumor growth by increasing tumor angiogenesis.
RESULTS
Increased VEGF levels and permeability after LKB1 deletion Because LKB1-deficient mice exhibit abnormal VEGF expression, 17 we determined whether LKB1 deletion in the endothelium would affect VEGF levels. Primary lung ECs from wild-type (WT) and LKB1 endo − / − mice were isolated and cultured. Levels of two important endothelial markers, endothelial nitric oxide synthase and vascular endothelial-cadherin, were checked, with no change between WT and LKB1 endo − / − cells (Figure 1a ), which suggests no phenotypic changes in cells. VEGF protein and mRNA levels were increased in LKB1 endo − / − ECs (Figures 1a and b ). Furthermore, serum VEGF levels were increased in LKB1 endo − / − mice (Figure 1c ) and the mice showed more VEGF-positive staining in endothelium on immunohistochemistry ( Figure 1d ). Hence, endothelial LKB1 deletion increased VEGF levels in ECs.
VEGF is also a vascular permeability factor; 18 therefore, we evaluated the effect of LKB1 deletion on vascular permeability. To quantify vascular leakage, mice were injected with Evans blue. The amount of dye leaked was greater in tissues including the kidney, liver, lung and skin from LKB1 endo − / − than WT mice ( Figure 1e ), which suggests that endothelial LKB1 deletion results in increased vascular permeability. Besides, aortas from WT and LKB1 endo − / − mice were examined to identify possible ultrastructural changes. Tight junctions between LKB1 endo − / − ECs were significantly smaller and wider than those between WT cells ( Figure 1f ). The mean length of tight junctions in ECs from LKB1 endo − / − mice was 52% of that from WT mice (Figure 1g ), which further confirmed the phenotype of hyperpermeability in LKB1 endo − / − mice.
Microalbuminuria is a marker of endothelial hyperpermeability and dysfunction, 19 and it can be determined by measuring the urinary albumin/creatinine ratio. Urinary albumin/creatinine ratio was significantly higher in LKB1 endo − / − than in WT mice ( Figure 1h ); therefore, LKB1 endo − / − mice exhibit microalbuminuria and hyperpermeability. To show the architecture of cell-cell contact, we used ZO-1 immunostaining of WT and LKB1 endo − / − ECs. LKB1 endo − / − cells showed increased permeability ( Figure 1i ). The morphological structure of glomerulus from WT and LKB1 endo − / − mice analyzed by hematoxylin and eosin staining showed LKB1 endo − / − mice with glomerular enlargement in the kidney (Figure 1j and Supplementary Figure 1 ). Taken together, LKB1 deletion increases VEGF level and permeability.
Tumors implanted in LKB1 endo − / − mice grew fast and showed microvascular permeability To address whether the loss of endothelial LKB1 affects tumor growth and vascular permeability, Lewis lung carcinoma (LLC) or B16F10 melanoma cells were implanted in the backs of WT and LKB1 endo − / − mice, and then tumor growth was monitored for 14 days and tumors were excised; LLC tumors grew faster in LKB1 endo − / − than in WT mice (Figure 2a ). Similarly, B16F10 melanoma tumors grew faster in LKB1 endo − / − than in WT mice ( Figure 2b ). To detect the vascular permeability in LLC tumors, Fluorescein isothiocyanate (FITC)-labeled dextran was injected: the area of extravasated dextran was increased in LLC tumors from LKB1 endo − / − mice ( Figure 2c ). In addition, Evans blue was injected into mice, and samples were quantified spectrophotometrically. Evans blue content was greater for LLC tumors from LKB1 endo − / − than WT mice ( Figure 2d ). Tumor permeability can be quantified by using macromolecular tracers, such as fibrin/fibrinogen staining. 20 Fibrinogen staining was greater for LLC tumors from LKB1 endo − / − than WT mice (Figure 2e ). Hence, tumors implanted in LKB1 endo − / − mice feature increased growth and microvascular permeability.
To determine which cell type-derived VEGF contributes to the different tumor growth in WT and LKB1 endo − / − mice, we stained LLC tumors from WT and LKB1 endo − / − mice for VEGF and found no difference in VEGF staining between the mice (Supplementary Figure 2A ). Then, we detected EC-or macrophage-derived VEGF levels by co-staining CD31 or CD68 and VEGF. CD31 and VEGF but not CD68 and VEGF co-staining was significantly increased in tumors from LKB1 endo − / − mice (Supplementary Figure 2B and C), which suggests that EC-derived VEGF contributes to the different tumor growth in WT and LKB1 endo − / − mice. Moreover, we implanted LLC cells into the backs of WT and macrophagespecific LKB1 knockout (LKB1 macro − / − ) mice for 14 days. As expected, LLC tumors from WT and LKB1 macro − / − mice did not differ in size (Supplementary Figure 2D) ; therefore, macrophagederived VEGF is unlikely the major factor for aberrant tumor growth observed in tumor-implanted LKB1 endo − / − mice.
LLC tumors implanted into LKB1 endo − / − mice show increased angiogenesis Tumor angiogenesis was evaluated with an antibody to the endothelial-specific marker CD31. The vasculature was more dense for LKB1 endo − / − than WT LLC tumors ( Figure 3a ). Quantification of CD31-positive areas suggested increased angiogenesis in LLC tumors from LKB1 endo − / − than WT mice ( Figure 3a ). To evaluate the effect of endothelial LKB1 on tumor growth for a longer time, LLCs were implanted in WT and LKB1 endo − / − mice. After 28 days, LLC tumors were still larger in LKB1 endo − / − than WT mice ( Figure 3b ). CD31 staining revealed more vascularization in LKB1 endo − / − than WT tumors ( Figure 3c ). Then, we examined tumor cell proliferation with an antibody to Ki-67 antigen. Ki-67 staining was greater in tumors from LKB1 endo − / − than WT mice ( Figure 3d ). To detect apoptosis in tumors, we detected cleaved Caspase-3 level and found no significant difference in level between LKB1 endo − / − and WT tumors ( Figure 3e ), which suggests that endothelial LKB1 deletion did not affect tumor cell apoptosis. Hence, LKB1 endo − / − tumors may grow faster because of increased angiogenesis.
Injection of the VEGF-neutralizing antibody decreases angiogenesis and tumor growth Because LKB1 knockout increased VEGF levels in the endothelium, we determined whether the VEGF-neutralizing antibody could affect tumor growth in LKB1 endo − / − mice. Injection of the VEGFneutralizing antibody decreased serum VEGF level ( Figure 4g ) and tumor growth in WT and LKB1 endo − / − mice ( Figure 4a ); the IgG control antibody had no effect. Immunofluorescence with CD31 revealed that LKB1 deletion increased the vascular density of LLC tumors, and VEGF-neutralizing antibody treatment reduced the vascular density ( Figure 4b ). Therefore, LKB1 inhibits tumor angiogenesis and growth via a VEGF-mediated autocrine pathway.
To address whether tumor angiogenesis and growth were mediated by an LKB1/VEGF paracrine pathway, LLC and B16F10 cells were infected with control or LKB1 short hairpin RNA (shRNA) lentivirus to silence LKB1, and then implanted into WT mice. At the same time, mice were intravenously injected with the neutralizing monoclonal anti-VEGF antibody or control antibody. LKB1 silencing in B16F10 or LLC cells resulted in VEGF overexpression ( Figure 4h ) and enhanced tumor growth ( Figures 4c and e ). However, injection with the VEGF-neutralizing antibody reduced LLC and B16F10 tumor growth ( Figures 4c and e ). Immunofluorescence assay with CD31 revealed that LKB1 loss increased the vascular density of LLC and B16F10 tumors, and treatment with the VEGF-neutralizing antibody decreased the vascular density (Figures 4d and f) . Thus, LKB1/VEGF also regulates tumor angiogenesis and growth via a paracrine pathway. Increased angiogenesis in LKB1-deficient endothelium LKB1 deletion increased VEGF levels and permeability. Because vascular permeability contributes to the angiogenesis process in vivo, 21 we assessed whether LKB1 deletion affects angiogenesis.
The vascular system of the mouse retina provides a useful model to study angiogenesis. 22 We examined the developing retinal vasculature of WT and LKB1 endo − / − mice and found accelerated retinal vasculature outgrowth at P6 in LKB1 endo − / − pups ( Figure 5a ). In addition, LKB1 endo − / − retinas had more branch points, filopodia-containing tip cells and dilated vessels than WT retinas (Figure 5b ). To detect retinal protein leakage, we injected 70-kDa FITC-dextran into mice via the tail vein. Protein leakage was increased in the retinas of LKB1 endo − / − mice (Figure 5c ), which was further confirmed by Evans blue content measurement (Figure 5d ). To test whether LKB1 regulates angiogenesis via VEGF, we silenced VEGF in WT and LKB1 endo − / − ECs, and then examined cell proliferation. The proliferation of LKB1-deficient cells was increased, and VEGF knockdown restored the proliferation of LKB1 endo − / − cells to normal conditions (Figure 5f ). In addition, results from wound healing assay suggested that LKB1 deletion enhanced cell migration, which could be inhibited by VEGF silencing (Figure 5g and Supplementary Figure 3 ).
To study the effect of acute knockdown of LKB1 on angiogenesis, human umbilical vein endothelial cells (HUVECs) were transfected with control or LKB1 shRNA lentivirus to silence LKB1, and then cell proliferation and migration was examined. Similar to LKB1-deficient lung ECs, LKB1 knockdown increased VEGF expression, cell proliferation and migration ( Supplementary  Figure 4 ). To detect whether re-expression of LKB1 could rescue the phenotype in LKB1-deficient cells, LacZ or LKB1 plasmid was transfected into WT and LKB1 endo − / − ECs, and then cell proliferation and migration was examined. LKB1 deletion increased VEGF level released from ECs, and re-expression of LKB1 reduced VEGF level ( Figure 5i ). As expected, re-expression of LKB1 decreased the overproliferation and -migration observed in LKB1 endo − / − cells (Figures 5j and k) .
To further confirm whether LKB1 regulation of endothelial proliferation and migration depends on VEGF, we transfected control or VEGFR2 short interfering RNA into WT or LKB1 endo − / − cells, then examined cell proliferation and migration. VEGFR2 knockdown rescued the phenotype of overproliferation and -migration observed in LKB1 endo − / − mice (Figures 5m and n) . Hence, LKB1 deficiency enhances angiogenic processes, including cell proliferation and migration, by increasing VEGF level.
LKB1 negatively regulates VEGF expression
To explore how LKB1 regulates VEGF expression, LKB1-deficient A549 lung cancer cells were transfected with LKB1 or LacZ plasmid; VEGF mRNA level was decreased with LKB1 transfection (Figure 6a ). To assess how LKB1 regulates VEGF transcription, we generated four luciferase plasmids progressively truncated for the mouse VEGF promoter (Figure 6b ). LKB1 transfection repressed luciferase activities in all truncated constructs (Figure 6c ), which suggests that the responsive element, regulated by LKB1, is located within the small and proximal fragment spanning from -150 base pairs to the transcription start site. Moreover, the LKB1 kinase-dead mutant plasmid (D194A) inhibited VEGF expression ( Figure 6c) ; therefore, LKB1 kinase activity may not be required for VEGF inhibition. The Sp1-responsive element is localized at the region between − 150 base pairs and the transcription start site of the VEGF promoter. Therefore, LKB1 may regulate VEGF expression through Sp1. AMPK activity was decreased in LKB1 endo − / − cells. 16 To determine whether AMPK is involved in the regulatory activity of LKB1 in VEGF expression, VEGF-luc plasmids were transfected into WT and LKB1 endo − / − cells, followed by AICAR (AMPK activator) treatment. AICAR did not change the VEGF expression ( Figure 6d ), which suggests that AMPK is not involved in the regulatory activity of LKB1 in VEGF transcription.
To determine whether LKB1 can bind to Sp1, HEK293T cells were transfected with WT LKB1 and green fluorescent protein-Sp1 plasmid. Cell lysates were immunoprecipitated with IgG or anti-LKB1 antibody, and then examined by western blot analysis with anti-green fluorescent protein antibody. LKB1 bound to Sp1 (Figure 6e ). This finding was further confirmed by reciprocal coimmunoprecipitation with cell lysates transfected with WT Sp1 and green fluorescent protein-LKB1 (Figure 6f ). To further determine the association of LKB1 and Sp1 in ECs, mouse lung EC lysates were immunoprecipitated with IgG or anti-LKB1 antibody, and then examined by western blot analysis with anti-Sp1 antibody. LKB1 was able to bind to Sp1 under physiological conditions (Figure 6g ). The colocalization of LKB1 and Sp1 was observed in the nuclei of ECs (Figure 6h ). However, LKB1 overexpression did not change Sp1 levels (Figure 6i ). Overall, these data indicate that LKB1 negatively regulates VEGF expression.
LKB1 binding with Sp1 inhibits VEGF expression
To map their binding domains, we constructed different truncated Sp1 and LKB1 plasmids (Figure 7a ). When the truncated Sp1 plasmids were co-transfected with LKB1 into HEK293T cells, only the C-terminal domain of Sp1 could bind to LKB1 (Figure 7b ). However, Sp1 could not bind to the truncated LKB1 plasmids (data not known), which suggests that full-length LKB1 is required for its binding to Sp1.
To detect whether LKB1 can affect the binding of Sp1 to the VEGF promoter, LacZ, WT or D194A LKB1 plasmid was transfected into A549 cells, and chromatin immunoprecipitation was performed. Both WT and D194A LKB1 inhibited Sp1 binding to the VEGF promoter (Figure 7c ). In ECs, chromatin immunoprecipitation assay showed more Sp1 binding with VEGF promoter in LKB1 endo − / − ECs (Figure 7d ). In addition, LKB1 endo − / − ECs were transfected with LacZ plasmid, WT or D194A LKB1 plasmids followed by DNA chromatin immunoprecipitation assay. Compared with LacZ, both WT and D194A plasmid inhibited Sp1 to bind with VEGF promoter (Figure 7e ), which suggests that the kinase activity of LKB1 is not required in regulating Sp1 binding to the VEGF promoter in ECs. In addition, LKB1 inhibited VEGF promoter activity in control short interfering RNA-transfected A549 cells but could not inhibit VEGF expression in Sp1-deficient cells (Figure 7f ), which suggests that LKB1 inhibits VEGF expression via Sp1. Moreover, mutation of the Sp1 element completely abolished the LKB1-mediated repression of the VEGF promoter ( Figure 7g ). Overall, these results demonstrate that LKB1 negatively regulated VEGF expression by competitively binding Sp1.
DISCUSSION
In mammals, two splice variants of LKB1 are expressed because of alternate use of 3′ exons. The long form is the main form widely expressed in tissues, whereas the short form has a unique 39-residue format instead of the last 63 residues in the long form and is a minor form in most tissues but is highly expressed in haploid spermatids. 23, 24 In our Cre/LoxP system, both LKB1 isoforms could be deleted in the endothelium. Our study is the first to show that EC-specific LKB1 knockout in mice increased VEGF levels, thus increasing angiogenesis and tumor growth. In WT ECs, LKB1 bound to the VEGF transcription factor Sp1 and decreased VEGF level. However, in LKB1-deficient ECs, the binding of Sp1 to the VEGF promoter was increased, and VEGF level, angiogenesis and tumor growth were enhanced (Figure 7h ). Moreover, treatment with VEGFneutralizing antibody decreased angiogenesis and tumor growth in LKB1 endo − / − mice. Thus, LKB1 has a critical role in regulating VEGF expression via Sp1 to maintain normal angiogenesis.
VEGF expression can be regulated by many transcription factors such as Sp1. 8 Sp1 can directly interact with the E3 ligase pVHL, thereby inhibiting Sp1 binding to the VEGF promoter. 25 In addition, p53 can form a complex with Sp1 to inhibit its binding with the VEGF promoter. 26 VEGF mRNA levels in LKB1 − / − embryos at embryonic day (E) 8.5 and E9.5 are elevated; therefore, LKB1 negatively regulates VEGF expression under normal conditions. 18 A recent study reported that LKB1 overexpression decressed Sp1 level, thereby downregulating VEGF. 27 However, we found that LKB1 did not alter Sp1 protein levels (Figure 6i ). We demonstrate that LKB1 could bind to Sp1 and inhibit its binding to the VEGF promoter, which may explain why LKB1 overexpression is significantly associated with a decrease in microvessel density 28 and LKB1 loss enhances the vascularity of Peutz-Jeghers syndrome polyps. 29 Besides affecting VEGF-mediated angiogenesis, LKB1 can affect other endothelial functions such as decreasing endothelial nitric oxide synthase activity with its deletion. 16 Knockdown of LKB1 with shRNA significantly lowers VEGF; therefore, tumor cells are important sources of VEGF. Besides tumor cells, other cells including macrophages and ECs can be potential sources of VEGF. To determine the relative contributions of ECs versus macrophages, we first co-stained VEGF with ECs (CD31) or macrophages (CD68). As expected, we found a strong co-staining of CD31 and VEGF in LKB1 endo − / − mice, with no difference of CD68 and VEGF co-staining in LKB1 endo − / − and WT mice. To further determine the contributions of macrophagederived VEGF, LLC cells were implanted in WT and macrophagespecific LKB1 knockout (LKB1 macro − / − ) mice. As expected, LLC tumors from WT and LKB1 macro − / − mice did not differ in size, which suggests that macrophage-derived VEGF did not contribute to the tumor growth in LKB1 endo − / − mice.
Findings from this study may have broad implications beyond cardiovascular diseases. Because the generation of blood supply in tumor is a rate-limiting step for tumor growth, any therapy for normalizing LKB1 expression or activity will suppress intra-tumoral microvessel formation, which will lead to limiting the supply of circulating blood that is crucial for tumor growth. Indeed, antiangiogenic therapy has been found effective in preclinical cancer studies, and numerous anti-angiogenic agents are being clinically evaluated. Notably, the US Food and Drug Administration has approved several anti-angiogenic drugs that target the VEGF signaling pathway.
In summary, this study identified the molecular mechanism of increased angiogenesis and tumor growth with LKB1 deficiency. LKB1 loss triggered the binding of Sp1 to the VEGF promoter, thereby enhancing VEGF expression. The development of therapeutic agents that target LKB1 in the treatment of pathological angiogenesis and tumor progression should be considered. 
MATERIALS AND METHODS Mice
The generation and characteristics of endothelium-specific LKB1-knockout mice (LKB1 endo − / − ) and macrophage-specific LKB1-knockout mice (LKB1 macro − / − ) were previously described. 16, 30 The animals were housed under specific pathogen-free conditions with a 12-h light/dark cycle with food and water freely available. At least five mice in each group were used in the animal study. A neutralizing monoclonal anti-VEGF antibody (2G11-2A05, Bio-legend, San Diego, CA, USA) or an isotype-matched control (RTK2758) was injected intravenously at 100 μg twice weekly, starting on the day of tumor implantation. All experiments were performed in accordance with the Animal Care and Use Committee of Georgia State University.
Tumor implantation
A total of 1 million LLC or B16F10 melanoma cells were injected subcutaneously into the backs of male WT or LKB1 endo − / − mice (6-8 weeks old). Tumors developed for 14 or 28 days and were measured every 2 days HEK293T cells were transfected with WT LKB1 and hemagglutinin (HA)-tagged truncated Sp1 plasmids, and cell lysates were immunoprecipitated with LKB1 antibody, and then they underwent western blot analysis with anti-HA antibody. (c) A549 cells were transfected with LacZ, WT or D194A LKB1 plasmid, and then they underwent DNA chromatin immunoprecipitation (ChIP) assay to detect the ability of Sp1 to bind to the VEGF promoter. *Po 0.05, compared with LacZ (n = 5). (d) WT and LKB1 endo − / − ECs were used in ChIP assay to detect the ability of Sp1 to bind to the VEGF promoter. *P o0.05, compared with WT (n = 5). (e) LKB1 endo − / − ECs were transfected with LacZ, WT or D194A, and then they underwent DNA ChIP assay. *P o0.05, compared with LacZ (n = 5). (f) Luciferase activity assay of A549 cells transfected with CTR siRNA or Sp1 siRNA for 48 h, and then with LacZ or LKB1, together with VEGF promoter-luciferase plasmids for 24 h. *Po 0.05, compared with LacZ (n = 5). (g) Luciferase activity assay of A549 cells transfected with LacZ or LKB1, together with WT or Sp1mutated VEGF promoter-luciferase plasmids, for 24 h. *Po 0.05, compared with LacZ (n = 5). (h) A diagram showing the mechanism by which LKB1 regulates endothelial angiogenesis and tumor growth via VEGF. Data are mean ± s.e. LKB1, angiogenesis and tumor growth W Zhang et al with use of calipers to assess tumor volume (length × height × width × 0.5236). In addition, LLC or B16F10 cells were infected with control or LKB1 shRNA lentiviral particles to silence LKB1, and then implanted into WT mice.
Transfection and luciferase assay A549 cells or ECs were transfected with the VEGF promoter-driven firefly luciferase plasmid, thymidine kinase promoter-driven renilla luciferase construct and the β-galactosidase (LacZ) control or LKB1 construct by using the 4D-Nucleofecto System (LONZA, Walkersville, MD, USA). At 24 h after transfection, luciferase activity was measured by using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA).
Statistical analysis
Data are presented as mean ± s.e. After confirming the normal distribution of data by the Kolmogorov-Smirnov test, differences between two groups were analyzed by Student's t-test. Assuming α = 0.5, β = 0.90, and a ratio of (expected effect size)/(expected standard deviation) = 1.20, we needed at least five samples per group. P o0.05 was considered statistically significant.
